Brilique 90 mg 56 tablets

Tradename

Brilique

Composition

Each tablet contains:

Ticagrelor 90 mg.

Auxiliary components:

mannitol, calcium hydrogen phosphate, sodium carboxymethyl starch, hyprolose, magnesium stearate.

Properties

Brilik@ contains ticagrelor, a member of the chemical class of cyclopentyltriazolopyrimidines, which is a selective and reversible direct acting P2Y12 receptor antagonist and prevents ADPmediated P2Y12-dependent platelet activation and aggregation. Ticagrelor does not prevent ADP binding, but its interaction with the platelet P2Y12 receptor prevents ADP-induced signal transduction. Because Platelets are involved in the initiation and / or developme of thrombotic complications of atherosclerosis, and inhibition of platelet function has been shown to reduce the risk of cardiovascular events such as death, myocardial infarction, or stroke.

Adenosine is formed locally in places of hypoxia and tissue damage by release from ATP and ADP. Ticagrelor inhibits ENT-I and prolongs Tl / 2 of adenosine, thereby increasing its local extracellular concentration, enhancing the local adenosine response. Ticagrelor has no clinically significant direct effect on adenosine receptors (Al, A2A, A2B, A3) and is not metabolized to adenosine. Adenosine has the following effects, which include: vasodilation, cardioprotection, inhibition of platelet aggregation, modulation of inflammation, and dyspnea, which can affect the clinical profile of ticagrelor. In healthy volunteers and in patients with acute coronar syndrome (ACS), ticagrelor has been show enhance the following effects of adenosine: vasodilation (assessed as increased coronary

blood flow in healthy volunteers; headache), inhibition of platelet function (in vitro in whole human blood), and dyspnea. However, the association of increased local concentrations of adenosine with clinical outcomes (morbidity and mortality) has not been proven.

Indications

In combination with acetylsalicylic acid:

— for the prevention of atherothrombotic complications in patients with acute coronary syndrome (unstable angina pectoris, myocardial infarction without ST segment elevation or myocardial infarction with ST segment elevation [STEMI]), including patients who received drug therapy and patients undergoing percutaneous coronary intervention or coronary artery bypass surgery

Method of administration and dosage:

Contraindications

hypersensitivity to ticagrelor or any component of the drug;

active pathological bleeding;

history of intracranial hemorrhage;

Side effects

Nervous system, psyche and sensory organs: confusion, dizziness, fainting, headache, intracranial hemorrhage, anxiety, insomnia.

Cardiovascular system, blood (hemostasis, hematopoiesis) and lymphatic system: arterial hypotension, tachycardia, arterial hypertension, bradycardia, chest pain, heart rhythm disturbances.

Digestive system: gastrointestinal bleeding (including bleeding from the gums, rectal bleeding, bleeding from a stomach ulcer),